Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

During the developing COVID-19 pandemic, the Nuffield Department of Medicine Research Building is taking measures to prevent the spread of the disease.

Departments are instructed by the University's Registrar to work from home and manage building closures.

This is to restrict any contact between individuals as far as possible.  The University remains open and operating as far as possible with the following restrictions:

  • Only essential activities should continue on site (e.g. research relating to Covid-19 or that of national importance, or the maintenance of research equipment.  Departments are responsible for defining what is essential, in line with divisional guidance, and should provide appropriate operating procedures.  PVC Research will be in touch with Divisions to assist in drawing up guidance.
  • Other research and teaching continues remotely where possible and students return home (if possible and where that has not already happened)
  • Departments physically close except where essential activities have to be done on site.  Staff work remotely where possible.  Only core support functions and other essential activities continue on site and only with critical staff on site - e.g. building access and maintenance, security, maintenance or research equipment.

WHAT IS TARGET DISCOVERY?

Target discovery helps identifying drug targets, molecules or molecular interactions at a critical point in a disease-causing pathway that are predicted to being amenable to therapeutic manipulation. The centre aims to link recent advances in genetics, genomics, cell and chemical biology for improved drug target discovery. A more specific focus for refining and validating such targets will provide a better link between traditional "open ended" academic processes to biomedical research and the need of the pharmaceutical industry for accurately defined targets to accelerate drug development.